Ischemic Stroke, Transient Ischemic Attack
Conditions
Keywords
IV-tPA, Activase, endovascular therapy
Brief summary
Limited access is a major hurdle in the treatment of AIS; many hospitals, especially rural hospitals, do not have the infrastructure or medical support to effectively treat AIS patients.5 Failure to recognize the signs and symptoms of stroke by the patient and/or emergency medical services (EMS) is another barrier to the timely treatment of AIS. Several studies, including the Paul Coverdell National Acute Stroke Registry (PCNASR), have reported low rates of adherence to stroke care guidelines, suggesting that many AIS patients do not receive proper treatment according to established guidelines. Thus, there remains an increasing need to assess and address the barriers that prevent patient access to proper AIS treatment. Annually, approximately 20,000 patients are discharged from Wisconsin hospitals with the diagnosis of stroke and an estimated 4,000 patients die from stroke each year in WI. To date, there have been no statewide studies initiated in Wisconsin to assess the regional barriers to the treatment of AIS patients with thrombolytic or endovascular therapy, and many hospitals do not routinely collect and analyze AIS patient data. The goal of the Improving Patient Access to Stroke Therapy (IMPACT) pilot study is to engage community hospitals statewide to identify the regional barriers to AIS therapy in WI.
Interventions
DRUGActivase
Patients treated with Activase
DEVICEEndovascular therapy
Patients treated with endovascular therapy, such as IA-tPA, mechanical thrombectomy, etc for acute ischemic stroke or transient ischemic attack.
Sponsors
Medical College of Wisconsin
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * Clinical diagnosis of acute ischemic stroke or transient ischemic attack (TIA) * ICD-9-CM code indicative of stroke or TIA
Exclusion criteria
* Clinical diagnosis of intracerebral hemorrhage or subarachnoid hemorrhage * Stroke or TIA occurred while patient was hospitalized
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of regional pre-hospital, hospital, and community barriers to stroke therapy | At end of study (12 months) |
Secondary
| Measure | Time frame |
|---|---|
| Total number of stroke patients treated with acute stroke therapy | At end of study (12 months) |
| Total number of stroke patients eligible to receive Activase® versus patients eligible but did not receive Activase® | At end of study (12 months) |
| Use of endovascular therapy in patients who received Activase® versus patients who did not receive Activase® | At end of study (12 months) |
Countries
United States
Outcome results
None listed